Sinjini Biswas

Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial

Markus P. Schlaich, M Bellet, Michael A. Weber et al. · The Lancet · 2022 · 206 citations · Full text

Molecular Pharmacology, Hypertension, Resistant Hypertension +9

Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial

Clara K Chow, Emily Atkins, Graham S. Hillis et al. · The Lancet · 2021 · 139 citations · Full text

Hypertension, Antihypertensive Therapy, Blood Pressure Medicines +7

Impact of Socioeconomic Status on Clinical Outcomes in Patients With ST-Segment–Elevation Myocardial Infarction

Sinjini Biswas, Nick Andrianopoulos, Stephen J. Duffy et al. · Circulation Cardiovascular Quality and Outcomes · 2019 · 54 citations

Impact of Pre-Procedural Blood Pressure on Long-Term Outcomes Following Percutaneous Coronary Intervention

Josephine Warren, Shane Nanayakkara, Nick Andrianopoulos et al. · Journal of the American College of Cardiology · 2019 · 45 citations

Percutaneous Coronary Intervention, Hypertension, Cardiovascular Disease +11

Association of Body Mass Index and Extreme Obesity With Long‐Term Outcomes Following Percutaneous Coronary Intervention

Sinjini Biswas, Nick Andrianopoulos, Diem Dinh et al. · Journal of the American Heart Association · 2019 · 32 citations · Full text